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Abstract 
Thermoplastic polyurethanes (TPUs) are widely used in biomedical applications due to 
their excellent biocompatibility. Their role as matrices for the delivery of small molecule 
therapeutics has been widely reported. However, very little is known about the release of 
bioactive peptides from this class of polymers. Here, we report the release of linear and cyclic 
peptides from TPUs with different hard and soft segments. Solvent casting of the TPU at 
room temperature mixed with the different peptides resulted in reproducible efflux profiles 
with no evidence of drug degradation. Peptide release was dependent on the size as well as 
the composition of the TPU. Tecoflex 80A (T80A) showed more extensive release than 
ElastEon 5-325, which correlated with a degree of hydration. It was also shown that the 
composition of the medium influenced the rate and extent of peptide efflux. Blending the 
different TPUs allowed for better control of peptide efflux, especially the initial burst effect. 
Peptide-loaded TPU prolonged the plasma levels of the anti-inflammatory cyclic peptide 
PMX53, which normally has a plasma half-life of less than 30 min. Using a blend of T80A 
and E5-325, therapeutic plasma levels of PMX53 were observed up to 9 days following a 
single intraperitoneal implantation of the drug-loaded film. PMX53 released from the blended 
TPUs significantly inhibited B16-F10 melanoma tumor growth in mice demonstrating its 
bioactivity in vivo.  This study provides important findings for TPU-based therapeutic peptide 
delivery that could improve the pharmacological utility of peptides as therapeutics.  
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1. Introduction 
 
Bioactive peptides are amongst the fastest growing class of therapeutics under 
development for the treatment of human disease. They can be highly specific and potent in 
their pharmacological effects, but suffer from limited modes of delivery, poor bioavailability 
and rapid clearance [1].  Not surprisingly, considerable effort has been made to formulate 
peptide-based drugs that enhance their availability or increase their biological stability [2]. 
This has led to a rapd growth in recent approvals of peptides as therapeutics [3]. One 
approach to overcome some of the limitations of peptides is to deliver them within a matrix 
that prevents their rapid clearance in the body and provides prolonged release over days or 
even months. Because of their high potency, peptides may be attractive candidates for 
sustained release formulations since much less drug is required compared to many small 
molecule therapeutics.  
Thermoplastic polyurethanes (TPUs) are widely used for implantable devices because of 
their excellent mechanical properties and biocompatibility [4, 5]. They also have proven 
versatility for the delivery of therapeutics such as antimicrobial agents, anticancer drugs and 
anti-inflammatory drugs [6-10]. TPUs can be synthesized from a wide variety of precursors 
for a range of biological applications. They comprise a mixture of hard and soft segments that 
are thermodynamically incompatible forming micro-domains as a result of polymerization-
induced phase separation [11, 12]. At ambient temperature, the high polarity of the hard 
segments creates non-covalent cross linking and cohesion between the polymer chains while 
the long soft segments impart flexibility. The micro-domains preferentially interact with 
different small molecule drugs depending on their physicochemical properties. Consequently, 
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as drug delivery matrices, TPUs can be formulated differently to suit the characteristics of the 
drug.  
Biodegradable TPU scaffolds can produce prolonged delivery of large proteins such as 
insulin-like growth factor [13], bone morphogenic protein-2 [14, 15] and platelet-derived 
growth factor [16]. However, there are very few studies on the release of peptides from 
different polyurethanes. Li et al reported the controlled release of insulin from biodegradable 
poly(ether-urethane) hydrogels over 10 days [17] while Wang et al recently showed that the 
peptide Bmap-28 could be released from the hydrophilic polyurethane PEGU25 over more 
than 20 days [18]. Both approaches used a biodegradable matrix for delivery and therefore 
were designed as stand-alone delivery systems. By contrast, non-degradable TPUs are widely 
used in medical devices and implants because they are soft and flexible but highly durable. 
This has been exploited for drug delivery by impregnating polyurethane-based implants such 
as catheters, coatings and dressings with different therapeutics [19-21]. A major advantage of 
using non-biodegradable TPU’s for drug delivery is their common use in components of 
implantable devices. Moreover, the biomedical TPUs are easily to cast and have high drug 
uptake capacity. However, there are few studies into the release of bioactive peptides from 
non-biodegradable TPUs or whether these polymers have any advantages as reservoirs for 
prolonged delivery of peptides in vivo. 
The goal of the current study was to investigate the release of peptides from medical-
grade non-biodegradable TPUs used with implantable devices. Several peptides developed 
for the treatment of inflammatory diseases were compared with a number of other linear and 
cyclic peptides to better understand how release of these molecules from the TPUs could be 
controlled. TPUs with different soft and hard segments were studied and the results 
demonstrate the flexibility of TPUs for controlled peptide release both in vitro and in vivo. 
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The novel approaches reported here have broad application and may improve the 
pharmacological utility of many peptides as therapeutics. 
 
2. Materials and methods 
 
2.1 Materials 
The polyurethanes ElastEon (E5-325) and Tecoflex 80A (T80A) were kindly supplied by 
AorTech Biomaterials Pty Ltd. PMX53 and SFTI-1 were synthesized as previously described 
[22, 23]. Xen2174 was a generous gift from Prof Richard Lewis (University of Queensland). 
All other peptides were synthesised by solid phase peptide synthesis with 9H-fluoren-9-
ylmethoxycarbonyl (Fmoc) chemistry on either 2-Cl-trityl chloride or Rink-Amide-MBHA 
resin using previously described procedures [24]. Resins, Fmoc-L-amino acids and reagents 
were obtained from Iris Biotech GmbH (Marktredwitz, Germany). The peptides were cleaved 
from resin using TFA with triisopropylsilane (TIPS) and H2O as scavengers (9.5:2.5:2.5 
TFA:TIPS:H2O) at room temperature for 2 hr. TFA was dried down to 1 ml with nitrogen, 
and the peptide was precipitated in ice-cold ether, filtered and dissolved in 50% CH3CN 
containing 0.05% TFA, then lyophilized.  The crude peptides were purified by RP-HPLC on 
a C18 column using a gradient of 0−80% B (Buffer A: H2O/0.05% TFA; Buffer B: 90% 
CH3CN/10% H2O/0.045% TFA) over 80 min. ESI-MS was used to confirm the molecular 
mass of the synthesized peptide.  All other chemicals were of analytical grade. 
 
2.2 Measurement of peptides by liquid chromatography-mass spectrometry (LC-MS) 
Peptides were analyzed by LC-MS using an Agilent API 3200 LC/MS/MS. Samples (5 
µl) were injected onto an Agilent C18 column 2.1 x 150 mm and eluted using a water-
acetonitrile gradient:  5% acetonitrile containing 0.1% formic acid linear increase to 100% 
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from 0 to 0.2 min, hold at 100% acetonitrile/0.1% formic acid from 0.2 to 5 min, and linear 
decrease to 5% acetonitrile/0.1% formic acid from 5.0 to 5.1 min, hold at 5% 
acetonitrile/0.1% formic acid for 20 mins, at the flow rate of 150 µl/min. The column 
temperature was 40oC and the sample plate temperature was 4oC. The different peptides were 
monitored at specific ions determined during assay validation experiments.  A standard curve 
for each peptide was constructed using the same extraction procedure as the samples.  
 
2.3 Preparation of peptide-loaded polyurethane films 
Each TPU was dried at 60°C for 1 day prior to use. They were then dissolved in 
dichloromethane at a concentration of 5% (wt/v). When peptides were co-solvent cast, they 
were dissolved in methanol and mixed with the TPUs solution. The mixed solution was 
poured into a Teflon dish and dried at room temperature for 3 hr in a stream of nitrogen gas. 
Films were then annealed under vacuum at room temperature until the weight reached 
equilibrium. Under these conditions, each of the peptides examined were stable, whereas 
heating to 60°C or using alternative solvents led to peptide degradation (data not shown). 
Films were typically 1-2 mm in thickness [25]. 
 
2.4 In vitro release of peptides from polyurethane films 
Peptide-loaded films were cut into 1 cm2, immersed in 4.5 ml medium (Milli Q water, 
PBS or 10% FBS in RPMI) with constant mixing on a rotating wheel at 37oC. Samples (0.4 
ml) were withdrawn at each time point and freeze-dried. For the release of peptide in RPMI 
with 10% FBS, acetonitrile containing 1% formic acid were added into each samples (3:1 
v/v) to precipitate proteins and samples were centrifuged at 13000 g for 10 min. Supernatant 
(1.4 ml) was withdrawn and freeze-dried. All samples were re-dissolved in 50 µl methanol 
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and centrifuged at 13000 g for 1 min to remove undissolved salts. Supernatant (5 µl) was 
analyzed by LC-MS as described above.  
 
2.5 Bioactivity of released peptide  
To measure the bioactivity of the peptide released from the TPU films, U937 cells, grown 
in RPMI 1640 medium with 10% FBS, 2 mM glutamine and penicillin (50 
U/ml)/streptomycin (50 µg/ml) at 37oC with 5% CO2, were differentiated with 1 mM N6-2’-
O-dibutyryladenosine 3’:5’-cyclic monophosphate for 48 h to increase cell surface expression 
of C5aR. Differentiated cells were centrifuged at 400 g for 5 min to remove the growth 
medium and resuspended in Fluo-4 NW dye solution (Invitrogen). Cells (125,000 cells per 
well) were plated in 96-well plates coated with polylysine in Fluo-4-NW dye solution, 
incubated for 30 min at 37oC and then centrifuged 400 g for 3 min. PMX53 (0.1 µM or 1 
µM), or solution containing released peptides, was added to each well. After 10 min, 
recombinant human C5a (10 nM) were added to each well and intracellular Ca2+ 
concentration was measured by recording fluorescence at an excitation wavelength of 495 nm 
and an emission wavelength of 516 nm. To examine the activity of the released PMX53, 0.4 
ml samples were collected after 72 hr. 
 
2.6 In vivo pharmacokinetic studies 
 
All animal experiments were performed in accordance with approval from the University 
of Queensland Animal Ethics Committee, Australia. Male C57BL/6 mice of 6 to 8 weeks old 
were housed in cages and given free access to standard food and water, and acclimated two 
days prior to surgery. The animals were anesthetized with 5% isoflurane in 100% oxygen and 
then maintained using 1 to 2% isoflurane in 100% oxygen. A small incision was made in the 
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abdomen and polyurethane films containing 200 µg of PMX53 were implanted. The incision 
was sutured and cleaned. The animals were allowed to recover from anaesthesia. This site 
was chosen for implantation because of the simplicity of the surgery (rapid recovery by the 
animals) and the practicalities of implanting a disc of ~ 5 mm diameter. It was also observed 
that absorption of PMX53 from the abdomen was rapid and complete (see Fig 6A). 
Blood samples were collected at each time point into heparinized tubes by cardiac 
puncture. The blood samples were immediately centrifuged at 13000 g for 1 min at room 
temperature. The plasma samples were collected. JPE1375 was added into each time point 
sample as an internal standard just prior to the addition of acetonitrile containing 1% formic 
acid (3:1 v/v) to precipitate proteins. Samples were centrifuged at 13000 g for 10 min. 
Supernatant was recovered and freeze-dried. All samples were re-dissolved in 50 µl methanol 
and centrifuged at 13000 g for 1 min to remove undissolved salts. Supernatant (5 µl) was 
injected into the LC-MS. A standard curve were prepared in plasma and processed using the 
same method. 
At each time point when the animals were sacrificed, the implanted films were collected 
and briefly rinsed in H2O. Films were dried using filter paper before immersing in 1 ml 
ethanol for 24 hr.  The amount of PMX53 in the methanol was measured using LC-MS. The 
amount of PMX53 released from films was calculated as the total amount PMX53 casted 
with each film minus the amount remaining in the film at the end of the experiment. 
 
2.7 In vivo pharmacodynamic studies 
To examine whether PMX53 released from TPU films retain its bioactivity, the effect of 
released PMX53 on B16-F10 melanoma tumor growth as evaluated. B16-F10 cells (ATCC, 
mouse melanoma) were cultured in vitro in DMEM medium containing 10% FBS, 2 mM 
glutamine, and penicillin (50 U/ml) /streptomycin (50 µg/ml) at 37oC with 5% CO2. When 
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the cells approached 80-90% confluent, cells were trypsinised and resuspended in PBS. Each 
C57BL/6 mouse was injected with  B16-F10 melanoma cells (200,000 in 100ul) 
subcutaneously in the rear right flank. Body weight was monitored daily. On the fourth day 
after cells injection, mice were anaesthetised and implanted with a blended T80A:E5-325 
(1:1) film with or without 200 µg of PMX53, as described above. Six days after injection of 
cells, mice were anesthetized and their tumors were measured with callipers every day until 
the tumor size reached 800 mm3, following which the animals were sacrificed. Tumor 
volume was calculated using the following formula: 
Volume =
length × width
2
 
 
2.8 Statistical analysis 
In vitro and in vivo drug release and tumor volume data were analyzed by ANOVA using 
Prism Software GraphPad. In vivo plasma levels of PMX53 were modelled by nonlinear 
least-squares regression (Prism Software, GraphPad) using various equations (see Results). 
Stability of peptides and Ca2+ measurement data were analyzed using the Student’s t-test.  All 
experiments were conducted at least in triplicate. Data are presented as mean ± s.e.m. 
 
 
3. Results 
 
3.1 In vitro release of peptides from TPUs 
 
A number of different linear and cyclic peptides (Table 1) were studied for release from 
two different biomedical grade TPUs, which differ in their hard and soft segment 
composition [25]. Tecoflex 80A (T80A) has a poly(tetramethylene oxide) soft segment and 
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an aliphatic 4,4’-methylenebis (cyclohexyl) (H12MDI) hard segment, while ElastEon 5325 
(E5-325) has a 4,4-methylenediphenyl hard segment and a mixed macrodiol of α,ω-hydroxy-
terminated poly-dimethylsiloxane and polyhexamethylene oxide soft segment. T80A has 
been used in cardiovascular applications [26], vascular grafts [27] and stent production [28] 
while E5-325 and its analogs have been employed in arthroplasty devices [29], pacing lead 
insulation and heart valves [30].  These different hard and soft segments produce polymer 
composites with different physical properties [25] and hemocompatabilities [31].  The 
peptides chosen for this study ranged in molecular weights from 830 to 1500 daltons and 
target several different receptors in vivo (Table 1).  
Typical release profiles for each of the peptides from T80A are shown in Fig. 1. There 
was considerable variation between the rate and extent of release for the different peptides, 
although all reached equilibrium by 48 hr. The smaller molecules (PMX53, PXM201 and 
PMX205 [32]) showed similar release profiles reaching more than 70% by 72 hr. By contrast, 
the larger peptides (SFT-1 and Xen2174) showed very little release over this time. For the 
linear peptide (JPE1375 [33]), approximately 30% of the drug was released over 72 hr.  
Efflux of the different peptides from T80A and E5-325 with respect to molecular size is 
shown in Fig 2. For T80A, there was a significant correlation between cumulative release 
over 72 h and molecular weight (R2 = 0.911, p < 0.05). This is in agreement with the very 
rapid release of the small molecule drug rhodamine (Mol wt 479)) reported previously [25]. 
Release of the peptides from E5-325 was much less than from T80A (Fig 2B) and the 
relationship with size was less significant (R2 = 0.581).  
The rate of drug release from polymeric matrices has been positively correlated with the 
rate of hydration [34, 35]. For T80A and E5-325, water uptake over 24 hr was 4.3 ± 0.2 and 
2.1 ± 0.1% of the weight of the film, respectively. This difference is in keeping with the 
faster efflux of the peptides from T80A compared to E5-325 (Fig 2).  
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3.2 Release of peptides from T80A: effect of media composition. 
 
Due to the relatively low release of each peptide from E5-325, T80A was chosen for 
further characterization using the cyclic peptide PMX53 and the linear peptide JPE1375. The 
efflux of PMX53 (Fig 3A) and JPE1375 (Fig 3B) was studied in water, phosphate buffered 
saline (PBS) and 10% fetal bovine serum in cell culture medium (FBS + RPMI 1640). For 
PMX53, there was a significant increase in the initial release (burst effect) when incubated in 
PBS. This was further enhanced in FBS + RPMI 1640. However, after 4 hr, the rate of release 
was linear and independent of the media used.  
For JPE1375, a different release profile was observed. Firstly, efflux was essential first-
order with little evidence of a burst effect. Secondly, while PBS enhanced JPE1375 release, 
FBS + RPMI 1640 did not. Indeed, after 24 hr, there was a significant decrease in the drug 
concentration in the medium (Fig 3B). This was due to instability of the peptide in the serum, 
and highlights an advantage of cyclized peptides that are less prone to protease-mediated 
degradation. 
  
3.3 Release of PMX53 from blended TPUs  
 
Following the observation that peptide release from different TPUs was markedly 
different, efflux from films generated by mixing T80A with E5-325 was investigated. 
Because of incompatibility of the hydrophilic hard and hydrophobic soft segments, the 
blended TPUs generate different micro-domains compared to the individual TPUs. It was 
reasoned that these different micro-domains may affect drug efflux by influencing the 
distribution of PMX53, the degree of peptide-polymer interaction or the rate of hydration of 
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the matrix.  For these experiments, PMX53 efflux was determined in FBS-RPMI 1640. Fig 
4A shows the progressive decrease in peptide efflux as the percent E5-325 increased. This 
was primarily due to an inhibition of the burst effect over the first 4 hr of drug release (Fig 
4B).  After 4 hr, efflux was essentially linear regardless of the TPU mixture used. When 
PMX53 efflux from the 50:50 blend of the two TPUs was examined over 21 days, release 
remained linear over the entire time period (Fig. 4C).  Release of PMX53 from E5-325 over 
the same time period was minimal.  
 
3.4 Bioactivity of PMX53 released from T80A 
 
To determine whether PMX53 released from the TPUs was biologically active, the 
ability of the peptide following efflux from T80A to inhibit C5a-mediated Ca2+ mobilization 
in U937 cells was determined.  Fig. 5 shows that 0.1 and 1 µM PMX53 inhibited C5a-
mediated Ca2+ mobilization by 30% and 99%, respectively. This is consistent with the known 
potency of PMX53 against the C5a receptor [36]. The drug in the medium after 72 hr was 
approximately 0.6 µM (Fig 3A) and this inhibited C5a by 89% indicating the PMX53 
retained its biological activity during casting of the films and following release. 
 
3.5 In vivo pharmacokinetics of PMX53 released from TPUs 
 
PMX53 administered intraperitoneally was rapidly absorbed and eliminated with a half-
life less than 20 min (Fig 6A). This is similar to the reported elimination of the drug in rats 
[37, 38]. When T80A films loaded with 200 µg of PMX53 were implanted in the peritoneal 
cavity, the time to peak plasma concentration was extended to 2.5 hr after which plasma 
levels decreased to less than 10 ng/ml by 24 hr (Fig 6B). The results shown in Fig 6B were 
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further analyzed by fitting a one-compartment model with first-order absorption and 
elimination to the data: 
 
																																										C = 	
	∙	
 	∙	()
(e 	! − e	!)							                         (1) 
 
where # is the concentration of PMX53 in plasma at time $, &'  is the volume of 
distribution,	() is the absorption rate constant and (* is the elimination rate constant. The 
pharmacokinetic parameters for the efflux of PMX53 from T80A are shown in Table 2 and 
the goodness of fit is shown in Fig 6B (solid line). The volume of distribution (412 ml) 
indicated that PMX53 distributes extensively into peripheral tissues, which may account, in 
part, for the very short plasma half-life of the drug in vivo. 
When PMX53 (200 µg) was administered in a 50% blend of T80A and E5-325, the time 
to peak plasma concentration was similar to that seen with T80A implants, although the 
maximum concentration was less (Fig 6C). This resulted from the slower rate of efflux from 
the implanted polymer disc, as shown in Fig 6D. At 24 hr, the plasma concentration was 
approximately 40 ng/ml, which slowly decreased to 20 ng/ml by day 9 (Fig 6C). The release 
of drug from the films recovered at sacrifice showed an initial burst effect (Fig 6D) followed 
by linear release up to 9 days (Fig 6E). 
Equation 2 was fitted to the data of PMX53 released from the blended TPUs. The model 
comprised a single compartment with first-order absorption and elimination along with an 
infusion component, which represented the constant release of PMX53 from the polymer 
after the initial burst effect: 
 
                       C=	 	∙	
+	∙	()
(e	! − e	,) +
.
/	∙	
(1 − e(!1))             (2) 
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where (2 is infusion rate, determined by the slow rate of efflux from 50% T80A after lag 
time. 3' is the lag time. For 50% T80A, (* was assumed to be equal to the (* determined in 
modeling release from T80A as it is independent of the TPU used. V1 is the volume of 
distribution in the first rapid release process while V2 is the volume of distribution during the 
infusion process. The resulting kinetic parameters are shown in Table 2. 
The initial burst effect, measured over the first 4 hr, accounted for approximately 25% of 
the total drug released from the implant (Fig 6E). The area under the concentration-time 
profile (AUC) was 6 fold greater for the blended TPUs compared to T80A alone. This is 
consistent with the larger amount of drug released from the blended TPUs (Fig 4D & E). The 
predicted infusion rate was 615 ng/hr (Table 2), which is similar to the efflux rate of PMX53 
from the implant in vivo (576 ng/hr – Fig 6E, dotted line).   
The model predicted that the volume of distribution was large at early time points, 
similar to that seen with the T80A implants. At later time points, the volume of distribution 
decreased to only 33 ml. Time-dependent changes in the apparent volume of distribution is 
indicative of target-mediated drug disposition[39].  
 
3.6 In vivo bioactivity of PMX53 released from blended TPUs 
 
To determine whether the sustained release of PMX53 in vivo could lead to a significant 
biological effect, the growth of B16-F10 melanoma cells in C57 black mice was investigated.  
Fig 7A shows the change in body weights for animals implanted with a blended TPU (50% 
T80A, 50% E5-325) with and without PMX53. There were no differences between the two 
groups indicating no overt toxicity due to the drug. Fig 7B shows a significant delay in tumor 
growth in mice implanted with PMX53 compared to controls (2-way ANOVA, p < 0.01). 
Survival curves (Fig 7C) also showed a significant increase in survival for mice implanted 
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with films containing PMX53 (Chi Squared, P < 0.01). These results demonstrated that 
PMX53 released from implanted TPUs exerts a biological effect, impairs tumor growth and 
prolongs the survival time in the B16-F10 melanoma model.  
 
4. Discussion 
 
 There has been a growing interest in the development of therapeutic peptides because 
of their specificity and potency [1]. However, peptides have poor bioavailability and very 
short circulation times in vivo, often limiting their clinical use. The current study has shown 
that biocompatible TPU implants may be a simple and effective means for controlling peptide 
delivery in vivo. These polymers have been widely used in medicine and can be 
manufactured using a variety of hard and soft segments. Polyurethanes are used to 
manufacture stents, catheters, pacemaker leads, heart valves, and as components of 
implantable devices such as artificial joints, spine stabilization devices and disc repacements 
[40, 41].  Impregnating these polymer components with therapeutics to minimize infections, 
clotting or inflammatory responses has been reported [19-21], although peptide release has 
not been extensively investigated.  
 Drug loading into polymer matrices can be achieved by a variety of different 
approaches [42-44]. Here, co-casting of the polyurethane in a solvent compatible with the 
peptides resulted in high loading with no detectable degradation. This method was not only 
simple but also maximized the amount of drug in the polyurethane, an important outcome for 
expensive material such as peptides. Two commonly used medical-grade TPUs were studied: 
Tecoflex 80A (T80A) and Elast-Eon E5-325.  Both are aliphatic polyether polyurethanes 
with different hard and soft segments. The arrangement of these segments creates different 
compartments within the polymer matrix [25]. Peptide release kinetics from both TPUs 
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correlated with peptide size and the rate of polymer hydration. The efflux of small molecule 
drugs from TPUs is also influenced by the osmotic effects of different solutes. This is 
particularly evident with polymeric hydrogels [45]. As water diffuses into TPU films, it has at 
least 2 effects. Firstly, it solubilizes the crystalline drug embedded in the film allowing it to 
diffuse out of the polymer. Secondly, it hydrates the polymer backbone and induces swelling, 
which is primarily dependent on the soft segment composition [46]. Hydration initially 
occurs very rapidly followed by an exponential decrease in water uptake, may explain the 
greater burst effect observed with the T80A polymer compared to E5-325. In sustained drug 
release models, a burst effect can be advantageous as it rapidly increases the target drug 
concentration at early time points, similar to a loading dose given before a constant drug 
infusion.  
 Previous work has demonstrated that tumour growth is enhanced by an inflammatory 
environment [47], and that anti-inflammatory drugs decrease the risk of certain cancers such 
as gastric, colon and breast [48, 49]. PMX53 has been shown to affect ovarian cancer 
proliferation by inhibiting neovascularization [50] and to inhibit TC-1 tumor formation in a 
mouse model [51], albeit only following multiple dosing regimens. In addition, PMX53 
inhibited the proliferation of B16-F10 melanomas in a syngeneic animal model [52]. In the 
present study, the effect of TPU-impregnated PMX53 on B16-F10 melanoma growth was 
assessed. PMX53 plasma levels remained elevated for at least 9 days when implanted in a 
50:50 mixture of T80A and E5-325A. Moreover, a significant decrease in tumor proliferation 
and survival was seen. These data show that peptide release from the TPU matrix was not 
only sustained but the peptide remained pharmacologically active in vivo. 
 This is the first study to demonstrate that the release of a drug from TPUs can be 
modified by blending the different polymers. Indeed, different mixtures resulted in different 
burst effects and rates of drug release. In practice, blending TPUs can be tailored not only for 
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peptide with different physical properties, but also for other drugs to fine-tune their release 
kinetics. This study provides important findings for TPU-based therapeutic peptide delivery 
that could improve the pharmacological utility of peptides as therapeutics.  
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Table 1 
The chemical structure of peptides used in the current study. 
 
Name Mol Wt Structure Target 
PMX53 895 
Ac-Phe-Orn-Pro-Cha-Trp-Arg 
            |______________| 
 
C5α receptor 
JPE1375 954 
Ho-Phe-Orn-Pro-Hle-Phe-Phe-NH2 
 
 
C5α receptor 
PMX201 896 
Ac-Phe-Orn-Pro-Cha-Trp-Cit 
            |______________| 
 
C5α receptor 
PMX205 838 
Hyc-Orn-Pro-Cha-Trp-Arg 
       |______________| 
 
C5α receptor 
SFT-1 1512 
Gly-Arg-Cys-Thr-Lys-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro-Asp 
         ______________________       
   ______________________________________ 
 
Protease 
Xen2174 1403 
Glu/Gln-Gly-Val-Cys-Cys-Gly-Tyr-Lys-Leu-Cys-His-Orn-Cys 
                 _______________         
             ____________________________ 
 
Noradrenalin 
transporter 
 Ho = l-hydroorotic acid, Hle = d-homoleucine, Cit = citulline, Cha = cyclohexylalanine, Hyc 
= hydrocinnamate. All other amino acids are represented by their standard 3 letter codes. 
 
 
 
 
 
Table 2  
Pharmacokinetic parameters for the efflux of PMX53 from T80A and from 50% T80A in 
vivo. 
 
TPU 
AUC 
(ng 
h/ml) 
t1/2 
(h) 
Vd 
(ml) 
() 
(hr-1) 
(* 
(hr-1) 
(2 
(ng/hr) 3' (hr) 
T80A 907 0.98 412 0.32 0.7 - - 
50% T80A, 
50% E5-325 5441 0.98 
V1 =282 
V2 =33 
0.79 0.7 615 0.29 
AUC: area under the curve; t1/2: half-life; Vd: volume of distribution; () : absorption rate 
constant; (*: elimination rate constant; (2: infusion rate; 3': lag time. 
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Legends to Figures: 
 
Fig 1. Time dependent release of peptides from T80A. ● PMX205,  PMX201, ο PMX53, 
 JPE1375,  Xen2174,  SFT-1. Each point is the mean ± s.e.m., n = 3. 
 
Fig 2. Effect of size (molecular weight) on the release of peptides from TPUs. A. 
Relationship between the cumulative release of peptides from T80A over 72 hr and their 
molecular weights. B. Relationship between the cumulative release of peptides from E5-325 
over 72 hr and their molecular weights. 
 
Fig 3. Efflux of C5aR antagonists from T80A in different media. Efflux of PMX53 (A) and 
JPE1375 (B) from T80A in PBS (), 10%FBS-RPMI (●) and H2O (ο). All data are mean ± 
s.e.m, n = 3. * = significantly different to H2O by ANOVA ( p < 0.001) 
 
Fig 4. Effect of blending TPUs on the release of PMX53.  (A) Efflux of peptide from films 
comprised of different percentages of each TPU over 3 days in 10% FBS-RPMI 1640. (B) 
The initial burst effect, measured as release over the first 4 hr, increased as the percent T80A 
increased. (C)  Efflux of PMX53 from 50% T80A and E5-325 over 21 days in 10% FBS-
RPMI1640. All results are mean ± s.e.m, n = 3. * = significantly different to T80A by 
ANOVA (p < 0.001) 
 
Fig 5. Bioactivity of PMX53 following efflux from T80A TPU. Differentiated U937 cells 
were pre-treated with PMX53 or released peptide and then exposed to 10 nM C5a. Calcium 
mobilisation was quantified and normalised to C5a alone. Data are mean ± s.e.m, n = 3. 
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Asterisks indicated significant difference compared to C5a alone by 1 way ANOVA (* = p < 
0.01; ** = p<0.001). 
 
Fig 6. PMX53 plasma levels following intraperitoneal administrated. (A) PMX53 plasma 
levels following administration of 1 mg/kg PMX5. (B) PMX53 plasma levels following 
implantation of PMX53-loaded (200 µg) T80A into the peritoneal cavity. The solid curve 
represents the predicted plasma concentrations from equation 1. (C) PMX53 plasma levels 
following implantation of PMX53-loaded (200 µg) blended TPU (50% T80A 50% E5-325) 
into the peritoneal cavity. The solid curve represents the predicted plasma concentrations 
from equation 2. (D) The in vivo efflux of PMX53 from T80A (ο) and 50% T80A, 50% E5-
325 (●) over 24 h. (E) The in vivo efflux of PMX53 from the blended TPU over 9 days. 
Dotted line indicates the linear efflux of PMX53 with time. All results are mean ± s.e.m, n 
=3. Asterisks indicated significant difference compared to T80A by ANOVA (p < 0.001) 
 
Fig 7. Effect of PMX53 released from TPUs on B16-F10 melanoma tumor growth. (A) Body 
weight of mice implanted with 50% T80A films or PMX53-loaded 50% T80A. (B) Tumor 
growth in mice implanted with 50% T80A/50% E5234 or PMX53-loaded (200 ug) blended 
TPU. There was a significant difference in tumour growth between the two groups (p > 0.01, 
ANOVA) (C) Survival curves of mice implanted with blank 50% T80A films or PMX53-
loaded 50% T80A. All results are mean ± s.e.m, n = 6. Asterisks indicated significant 
difference compared to TPU alone by ANOVA (p < 0.001) 
 
  
  
  
  
  
  
  
  
  
Statement of Significance. 
 
Therapeutic peptides can be highly specific and potent pharmacological agents, but are 
poorly absorbed and rapidly degraded in the body. This can be overcome by using a matrix 
that protects the peptide in vivo and promotes its slow release so that a therapeutic effect can 
be achieved over days or weeks. Thermoplastic polyurethanes are a versatile family of 
polymers that are biocompatible and used for medical implants. Here, the release of several 
peptides from a range of polyurethanes was shown to depend on the type of polymer used in 
the polyurethane. This is the first study to examine polyurethane blends for peptide delivery 
and shows that the rate and extent of peptide release can be fine-tuned using different hard 
and soft segment mixtures in the polymer.  
 
